New drug cocktail aims to outsmart Hard-to-Treat cancers
NCT ID NCT06722183
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase 2 trial is testing a combination of two drugs—futibatinib (a targeted therapy) and tislelizumab (an immunotherapy)—in people with colorectal cancer and other solid tumors that have spread. The study aims to see if the combo can shrink tumors and how safe it is. About 33 participants will be enrolled, and researchers will also look for biological markers that predict response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Campus Virchow Klinikum (CVK)
NOT_YET_RECRUITINGBerlin, Germany
Contact
-
Hope Hamburg
RECRUITINGHamburg, Germany
Contact
-
Kliniken Essen-Mitte
RECRUITINGEssen, Germany
Contact
-
Klinikum München rechts der Isar
RECRUITINGMünchen, Germany
Contact
-
Klinikum St. Marien Amberg
NOT_YET_RECRUITINGAmberg, Germany
Contact
-
Krankenhaus Nordwest
RECRUITINGFrankfurt am Main, 60488, Germany
Contact
-
Leopoldina Krankenhaus Schweinfurt
RECRUITINGSchweinfurt, Germany
Contact
-
MVZ für Hämatologie und Onkologie Ravensburg GmbH
NOT_YET_RECRUITINGRavensburg, 88212, Germany
Contact
-
Universitätsklinikum Düsseldorf
RECRUITINGDüsseldorf, Germany
Contact
-
Universitätsmedizin Mainz
NOT_YET_RECRUITINGMainz, Germany
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Futibatinib (a targeted cancer drug) combined with tislelizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new combination treatment option for colorectal cancer and other solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply to all patients. The combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.